We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Benign Hematology

Journal Scan / Research · September 26, 2021

Carfilzomib, Lenalidomide, and Dexamethasone With Lenalidomide Maintenance as Early Intervention in High-Risk Smoldering Multiple Myeloma

JAMA Oncology


Additional Info

JAMA Oncology
Carfilzomib, Lenalidomide, and Dexamethasone Followed by Lenalidomide Maintenance for Prevention of Symptomatic Multiple Myeloma in Patients With High-risk Smoldering Myeloma: A Phase 2 Nonrandomized Controlled Trial
JAMA Oncol 2021 Sep 16;[EPub Ahead of Print], D Kazandjian, E Hill, A Dew, C Morrison, J Roswarski, N Korde, M Emanuel, A Petrosyan, M Bhutani, KR Calvo, A Dulau-Florea, M Kwok, MJ Lee, S Lee, L Lindenberg, S Mailankody, E Manasanch, I Maric, E Mena, N Patel, N Tageja, JB Trepel, B Turkbey, HW Wang, W Wang, C Yuan, Y Zhang, R Braylan, P Choyke, M Stetler-Stevenson, SM Steinberg, WD Figg, M Roschewski, O Landgren

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading